Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q1- Text added to 2019 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
AbbieVie, attempt, Aubagio, Avonex, Bayer, behalf, Betaseron, circumstance, Copaxone, CRL, duly, EC, exceeded, exhibit, Extavia, formatted, frequency, Genzyme, Gilenya, Glatopa, Idec, Impel, incorporate, Inline, Instance, intranasally, IRS, Lemtrada, Linkbase, lived, Merck, Neuropharma, Page, physical, Plegridy, procedure, pursuing, quantitative, Rebif, recommending, recoverability, redacted, regularly, restart, Rituxan, Roche, Sandoz, Sanofi, Schema, Secretary, Serono, sudden, symptom, Taxonomy, Tecfidera, thereunto, Tysabri, undersigned, undiscounted, XBRL, Zinbryta
Removed:
American, bioavailability, bronchoconstriction, chest, commonly, description, discomfort, evidence, faster, feeling, headache, healthy, hot, ingredient, injection, large, median, nasal, partner, pharmacokinetic, poor, prescribed, profile, reversible, scientific, Society, spray, subcutaneously, tablet, Tmax
Valuein 2019 Q1 filing- Value in 2019 Q2 filing
Original filings
Filing view